Apimeds Pharmaceuticals US (APUS) Depreciation & Amortization (CF) (2025)
Apimeds Pharmaceuticals US (APUS) posted Depreciation & Amortization (CF) of $3985.0 for Q4 2025, up 167.63% on a QoQ basis from $1489.0 in Q3 2025.
Apimeds Pharmaceuticals US (APUS) Depreciation & Amortization (CF) (2025) Analysis & Trends
Apimeds Pharmaceuticals US's Depreciation & Amortization (CF) history runs 1 years deep, the most recent figure standing at $3985.0 for Q4 2025.
- Quarterly Depreciation & Amortization (CF) changed N/A year-over-year to $3985.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $5474.0 (changed N/A YoY) and the FY2025 annual result came in at $5706.0, changed N/A from the prior year.
- Depreciation & Amortization (CF) was $3985.0 for Q4 2025 at Apimeds Pharmaceuticals US, up from $1489.0 in the prior quarter.
- Across five years, Depreciation & Amortization (CF) topped out at $3985.0 in Q4 2025 and bottomed at $1489.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 239.00 Mn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 119.00 Mn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 1.04 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 22.60 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 676.10 Mn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 7.20 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 172.00 Mn |
| 10 | Apimeds Pharmaceuticals US | 8.17 Mn | 8.17 Mn | - | 3,985.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 3,985.00 |
| Dec 31, 2025 | 3,985.00 |
| Sep 30, 2025 | 1,489.00 |
| Sep 30, 2025 | 1,489.00 |